Last reviewed 2026-04-19 · How we verify

ADA-011

discontinued Monoclonal antibody

ADA-011 is being tested in a Phase 1 trial for patients with advanced solid tumors.

ADA-011 is an investigational drug in Phase 1 trials for advanced solid tumors. No mechanism of action or efficacy data are provided in the source.

At a glance

Generic name	ADA-011
Modality	Monoclonal antibody
Therapeutic area	Oncology
Phase	discontinued

Mechanism of action

ADA-011 is an experimental therapy currently being evaluated in early-stage clinical trials. It is being investigated for use in patients with advanced solid tumors, which are cancers that have spread beyond their original site. The drug is in the earliest phase of human testing, where researchers are primarily focused on determining safe dosage levels and initial signs of effectiveness.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors (Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ADA-011 CI brief — competitive landscape report
ADA-011 updates RSS · CI watch RSS
portfolio CI